# CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

> **NCT03002623** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 7 (actual)

## Conditions studied

- Thyroid Neoplasms
- Poorly Differentiated and Undifferentiated Thyroid Cancer
- Differentiated Thyroid Cancer

## Interventions

- **DRUG:** CUDC-907

## Key facts

- **NCT ID:** NCT03002623
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-22
- **Primary completion:** 2018-02-12
- **Final completion:** 2018-02-12
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study was closed because investigator left the National Institutes of Health.
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002623, "CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03002623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*